Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ABEO
vs
S&P 500
ABEO
S&P 500
Over the past 12 months, ABEO has underperformed S&P 500, delivering a return of -9% compared to S&P 500's +17% growth.
Stocks Performance
ABEO vs S&P 500
Performance Gap
ABEO vs S&P 500
Performance By Year
ABEO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Abeona Therapeutics Inc
Glance View
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare genetic diseases. It tries to fix the underlying DNA problem behind a disorder, rather than just treating symptoms. Its work has centered on diseases that affect the eyes, the immune system, and other inherited conditions with very limited treatment options. The company develops these therapies in-house and works through the long drug-development path of testing, seeking approval, and then bringing a treatment to market. Its customers are not everyday consumers; they are specialist doctors, hospitals, treatment centers, and the insurers or government programs that pay for rare-disease medicines. Abeona can make money through product sales if a therapy reaches the market, and it may also use licensing or collaboration deals tied to its drug candidates. What makes Abeona different is its role at the very high-risk, highly specialized end of the healthcare value chain. Instead of selling broad-usage medicines, it focuses on one-time or limited-use treatments for small patient groups where the scientific challenge is hard but the medical need is large. That makes the business much more dependent on clinical results, regulatory approval, and access to rare-disease treatment centers than a normal drug company.